MA47499A - Anticorps anti-tau et leurs procédés d'utilisation - Google Patents
Anticorps anti-tau et leurs procédés d'utilisationInfo
- Publication number
- MA47499A MA47499A MA047499A MA47499A MA47499A MA 47499 A MA47499 A MA 47499A MA 047499 A MA047499 A MA 047499A MA 47499 A MA47499 A MA 47499A MA 47499 A MA47499 A MA 47499A
- Authority
- MA
- Morocco
- Prior art keywords
- tau
- bodies
- methods
- tau bodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460642P | 2017-02-17 | 2017-02-17 | |
| US201762583400P | 2017-11-08 | 2017-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47499A true MA47499A (fr) | 2019-12-25 |
Family
ID=61563475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047499A MA47499A (fr) | 2017-02-17 | 2018-02-15 | Anticorps anti-tau et leurs procédés d'utilisation |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11370832B2 (fr) |
| EP (1) | EP3583123A1 (fr) |
| JP (1) | JP2020508054A (fr) |
| KR (1) | KR20190134997A (fr) |
| CN (1) | CN110520440A (fr) |
| AU (1) | AU2018221049A1 (fr) |
| BR (1) | BR112019017021A2 (fr) |
| CA (1) | CA3053379A1 (fr) |
| IL (1) | IL268658A (fr) |
| MA (1) | MA47499A (fr) |
| MX (1) | MX2019009817A (fr) |
| SG (1) | SG11201907422RA (fr) |
| TW (1) | TW201843175A (fr) |
| WO (1) | WO2018152359A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
| KR102471787B1 (ko) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
| AU2018221731C1 (en) | 2017-02-17 | 2021-11-18 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
| CA3061516A1 (fr) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Anticorps reconnaissant la proteine tau |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| TWI750419B (zh) * | 2017-10-16 | 2021-12-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| WO2019094576A1 (fr) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anticorps bispécifiques bace-tau |
| WO2019094608A1 (fr) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anticorps anti-bace1 et leurs procédés d'utilisation |
| MX2021001711A (es) * | 2018-08-16 | 2021-05-27 | Denali Therapeutics Inc | Proteínas biespecíficas modificadas. |
| AU2019326545A1 (en) * | 2018-08-22 | 2021-03-11 | Denali Therapeutics Inc. | Anti-HER2 polypeptides and methods of use thereof |
| WO2020180819A1 (fr) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Anticorps reconnaissant la protéine tau |
| WO2020242963A1 (fr) * | 2019-05-31 | 2020-12-03 | Eli Lilly And Company | Composés et procédés ciblant la protéine tau humaine |
| GB2585252A (en) * | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
| CN114930170A (zh) | 2020-01-02 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 用于测定脑中的治疗性抗体量的方法 |
| KR20220131246A (ko) * | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| IL302029A (en) | 2020-10-14 | 2023-06-01 | Denali Therapeutics Inc | Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023041805A1 (fr) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour l'amélioration de l'efficacité d'une thérapie par inhibiteur de hdac et la prédiction de la réponse à un traitement comprenant un inhibiteur de hdac |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3909084B2 (ja) * | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 微小管結合タンパク質タウに対するモノクローナル抗体 |
| EP1535930B1 (fr) | 2002-08-14 | 2010-10-06 | Mitsubishi Chemical Medience Corporation | Anticorps specifique de la proteine tau du système nerveux central |
| WO2005062977A2 (fr) | 2003-12-23 | 2005-07-14 | The Regents Of The University Of California | Anticorps humains d'internalisation specifiques du cancer de la prostate |
| US7456027B2 (en) | 2004-04-15 | 2008-11-25 | University Of Florida Research Foundation, Inc. | Proteolytic biomarkers for traumatic injury to the nervous system |
| US7435804B2 (en) * | 2004-10-19 | 2008-10-14 | Phage Biotechnology, Inc. | Method for obtaining single chain antibodies to human interferon α2b |
| US20070286858A1 (en) | 2006-03-21 | 2007-12-13 | Wyeth | Methods and Compositions for Antagonism of RAGE |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| CN103408661B (zh) | 2007-01-05 | 2016-04-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
| WO2011133919A1 (fr) | 2010-04-22 | 2011-10-27 | Janssen Alzheimer Immunotherapy | Utilisation de tau pour un suivi d'immunothérapie |
| US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| BRPI1013177A2 (pt) | 2009-05-28 | 2016-04-12 | Glaxo Group Ltd | construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA3120504A1 (fr) | 2009-06-10 | 2010-12-16 | New York University | Ciblage immunologique de proteines tau pathologiques |
| US20170315136A9 (en) | 2009-06-19 | 2017-11-02 | Banyan Biomarkers, Inc. | Biomarker assay of neurological condition |
| JP6124591B2 (ja) | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | タウオリゴマーに結合する抗体 |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US20130022982A1 (en) | 2009-09-14 | 2013-01-24 | Kevin Ka-Wang Wang | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
| TW201216985A (en) | 2010-10-07 | 2012-05-01 | Ac Immune Sa | Pharmaceutical composition |
| JP2014503178A (ja) | 2010-10-11 | 2014-02-13 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗タウ抗体 |
| US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| US9506051B2 (en) | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
| SG10201912964PA (en) | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| EP2764022B9 (fr) | 2011-10-07 | 2017-02-22 | AC Immune S.A. | Anticorps phosphospécifiques reconnaissant tau |
| JP6306513B2 (ja) | 2011-12-20 | 2018-04-04 | ヤンセン バイオテツク，インコーポレーテツド | 抗ＰＨＦ−ｔａｕ抗体及びその使用 |
| MX356800B (es) | 2012-04-05 | 2018-06-13 | Ac Immune Sa | Anticuerpo tau humanizado. |
| DK2857039T3 (da) | 2012-05-31 | 2019-12-16 | Univ Osaka City | Terapeutisk middel eller profylaktisk middel mod demens |
| CN104781278B (zh) * | 2012-07-03 | 2018-06-12 | 华盛顿大学 | 针对tau的抗体 |
| MX359817B (es) | 2012-08-16 | 2018-10-11 | Ipierian Inc | Anticuerpos que se enlazan a tau. |
| EP2906596B1 (fr) | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau |
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| EA035932B1 (ru) | 2012-12-21 | 2020-09-02 | Байоджен Ма Инк. | Человеческие анти-тау антитела |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
| MX2015012872A (es) | 2013-03-15 | 2016-02-03 | Ac Immune Sa | Anticuerpos anti-tau y metodos de uso. |
| CN105283196B (zh) | 2013-03-15 | 2018-10-12 | 贝丝以色列女执事医疗中心 | 用于产生和使用构象-特异性抗体的方法和组合物 |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| EP3041865A2 (fr) | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées |
| JP6629201B2 (ja) | 2013-11-27 | 2020-01-15 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| US20160333063A1 (en) | 2013-12-13 | 2016-11-17 | The General Hospital Corporation | Soluble high molecular weight (hmw) tau species and applications thereof |
| PL3083680T3 (pl) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
| EP2899208A1 (fr) | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci |
| AU2015213735A1 (en) | 2014-02-10 | 2016-08-04 | Merck Sharp & Dohme Corp. | Antibodies that bind to human Tau and assay for quantifying human Tau using the antibodies |
| NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| WO2015124540A1 (fr) | 2014-02-19 | 2015-08-27 | F. Hoffmann-La Roche Ag | Navette de la barrière hémato-encéphalique |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| CN107074935B (zh) | 2014-06-26 | 2021-08-03 | 扬森疫苗与预防公司 | 特异性结合微管相关蛋白tau的抗体和抗原结合片段 |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| DE102014013571A1 (de) | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
| CA3001724A1 (fr) | 2014-10-10 | 2016-04-14 | National Research Council Of Canada | Anticorps anti-tau et ses utilisations |
| US10323082B2 (en) | 2014-10-14 | 2019-06-18 | The Research Foundation For Mental Hygiene, Inc. | Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau |
| EP3786182A1 (fr) * | 2014-11-19 | 2021-03-03 | Axon Neuroscience SE | Anticorps anti-tau humanisés dans la maladie d'alzheimer |
| WO2016112078A2 (fr) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anticorps tau/anti-phf et leurs utilisations |
| MA41451A (fr) | 2015-02-04 | 2017-12-12 | Univ Washington | Constructions anti-tau |
| WO2016137950A1 (fr) * | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anticorps anti-tau |
| AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| CN107849124B (zh) * | 2015-06-05 | 2021-09-24 | 基因泰克公司 | 抗tau抗体及使用方法 |
| EP3313877B1 (fr) | 2015-06-24 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Anticorps anti-tau (ps422) humanises et procedes d'utilisation |
| JP6643364B2 (ja) | 2015-06-25 | 2020-02-12 | インスティテュート フォー マスキュロスケレタル サイエンス アンド エジュケイション，リミテッド | 移植用の椎体間固定装置およびシステム |
| MA41669A1 (fr) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Anticorps se liant a tau |
| US10287343B2 (en) | 2015-07-06 | 2019-05-14 | Ucb Biopharma Sprl | Tau-binding antibodies |
| US20200079825A1 (en) | 2015-07-13 | 2020-03-12 | The General Hostital Corporation | Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| PT3334761T (pt) | 2015-08-13 | 2023-08-17 | Univ New York | Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias |
| WO2017027685A2 (fr) | 2015-08-13 | 2017-02-16 | New York University | Molécules à base d'anticorps spécifiques de l'épitope asp421 tronqué de la protéine tau et leurs utilisations dans le diagnostic et le traitement de tauopathie |
| CN117069841A (zh) | 2015-10-06 | 2023-11-17 | 艾利妥 | 抗trem2抗体及其使用方法 |
| US20170138400A1 (en) | 2015-11-12 | 2017-05-18 | Schaeffler Technologies AG & Co. KG | Bainite hardened stack bearing |
| WO2017100632A1 (fr) | 2015-12-11 | 2017-06-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Variants tau associés à la maladie d'alzheimer et aux lésions cérébrales traumatiques chez l'humain utilisés en tant que biomarqueurs et leurs méthodes d'utilisation |
| ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
| KR102471787B1 (ko) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| CN109415434B (zh) | 2016-05-02 | 2022-12-30 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| WO2017194589A1 (fr) | 2016-05-10 | 2017-11-16 | Vib Vzw | Inhibition du dysfonctionnement synaptique précoce à médiation par tau |
| MY197836A (en) | 2016-07-12 | 2023-07-20 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| CA3030754C (fr) | 2016-07-20 | 2022-04-26 | Anahit Ghochikyan | Anticorps anti-tau humanises, compositions et procedes de fabrication et methodes d'utilisation dans le traitement, le diagnostic et la surveillance de tauopathies |
| US10870709B2 (en) | 2016-07-22 | 2020-12-22 | New York University | Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides |
| WO2018031361A2 (fr) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Polythérapie |
| US11072639B2 (en) | 2016-09-08 | 2021-07-27 | Regenerative Research Foundation | Bi-functional anti-tau polypeptides and use thereof |
| FR3058143B1 (fr) | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
| WO2018085653A1 (fr) | 2016-11-04 | 2018-05-11 | The Regents Of The University Of California | Compositions ciblant la protéine tau à triple répétition pour le traitement de troubles neurodégénératifs, et leurs procédés de fabrication et d'utilisation |
| US9914781B1 (en) * | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
| CR20230163A (es) | 2016-12-07 | 2023-07-06 | Genentech Inc | ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271) |
| AU2017373884A1 (en) | 2016-12-07 | 2019-05-30 | Ac Immune Sa | Anti-tau antibodies and methods of their use |
| CN110267985B (zh) | 2017-01-04 | 2023-05-23 | H.隆德贝克有限公司 | 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11249093B2 (en) | 2017-03-28 | 2022-02-15 | Janssen Vaccines & Prevention B.V. | Methods for detection of Tau protein aggregation modulating compounds |
| KR20190133191A (ko) | 2017-03-28 | 2019-12-02 | 얀센 백신스 앤드 프리벤션 비.브이. | 타우에 특이적으로 결합하는 결합 분자 |
| TW202400231A (zh) | 2017-03-28 | 2024-01-01 | 美商建南德克公司 | 治療神經退化性疾病之方法 |
| JP7278960B2 (ja) | 2017-03-28 | 2023-05-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 新規タウ種 |
| CA3061516A1 (fr) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Anticorps reconnaissant la proteine tau |
| JP2020529394A (ja) | 2017-06-16 | 2020-10-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | タウオパチーを治療するための組成物及び方法 |
| US10662246B2 (en) | 2017-07-10 | 2020-05-26 | New York University | Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy |
| EP4310496A2 (fr) | 2017-07-12 | 2024-01-24 | Dana-Farber Cancer Institute, Inc. | Composés pour la dégradation de la protéine tau |
| MX2020001171A (es) | 2017-08-01 | 2020-03-12 | Amgen Inc | Sistemas y metodos para realizar un ensayo de glicanos en tiempo real de una muestra. |
| TWI750419B (zh) | 2017-10-16 | 2021-12-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| WO2019094576A1 (fr) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anticorps bispécifiques bace-tau |
-
2018
- 2018-02-15 EP EP18708795.2A patent/EP3583123A1/fr not_active Withdrawn
- 2018-02-15 SG SG11201907422RA patent/SG11201907422RA/en unknown
- 2018-02-15 MX MX2019009817A patent/MX2019009817A/es unknown
- 2018-02-15 MA MA047499A patent/MA47499A/fr unknown
- 2018-02-15 WO PCT/US2018/018415 patent/WO2018152359A1/fr unknown
- 2018-02-15 JP JP2019545364A patent/JP2020508054A/ja active Pending
- 2018-02-15 CA CA3053379A patent/CA3053379A1/fr not_active Abandoned
- 2018-02-15 CN CN201880024720.8A patent/CN110520440A/zh active Pending
- 2018-02-15 AU AU2018221049A patent/AU2018221049A1/en not_active Abandoned
- 2018-02-15 KR KR1020197027036A patent/KR20190134997A/ko unknown
- 2018-02-15 BR BR112019017021A patent/BR112019017021A2/pt not_active Application Discontinuation
- 2018-02-21 TW TW107105837A patent/TW201843175A/zh unknown
-
2019
- 2019-08-12 IL IL26865819A patent/IL268658A/en unknown
- 2019-08-16 US US16/543,367 patent/US11370832B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190134997A (ko) | 2019-12-05 |
| US11370832B2 (en) | 2022-06-28 |
| BR112019017021A2 (pt) | 2020-04-14 |
| JP2020508054A (ja) | 2020-03-19 |
| US20200216522A1 (en) | 2020-07-09 |
| EP3583123A1 (fr) | 2019-12-25 |
| WO2018152359A1 (fr) | 2018-08-23 |
| IL268658A (en) | 2019-10-31 |
| MX2019009817A (es) | 2019-11-21 |
| AU2018221049A1 (en) | 2019-09-19 |
| CA3053379A1 (fr) | 2018-08-23 |
| TW201843175A (zh) | 2018-12-16 |
| SG11201907422RA (en) | 2019-09-27 |
| CN110520440A (zh) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
| MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA45280A (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
| MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci |